- Report
- May 2024
- 138 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- October 2024
- 198 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- March 2024
- 150 Pages
Global
From €4611EUR$4,850USD£3,873GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- April 2023
- 111 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- October 2023
- 181 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- February 2024
- 89 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Book
- November 2020
- 464 Pages
- Book
- July 2020
- 416 Pages

Vulvodynia is a chronic condition that affects the vulva, the external female genitalia. It is characterized by pain, burning, stinging, and itching in the vulvar area. Symptoms can range from mild to severe and can last for months or even years. The cause of vulvodynia is unknown, but it is believed to be related to nerve damage, hormonal imbalances, or an underlying medical condition. Treatment options include medications, physical therapy, lifestyle changes, and surgery.
The Vulvodynia market is an important part of Women's Health, as it affects millions of women worldwide. It is estimated that up to 16% of women experience vulvodynia at some point in their lives. Despite its prevalence, there is still a lack of awareness and understanding of the condition, which can lead to delays in diagnosis and treatment.
Companies in the Vulvodynia market include pharmaceutical companies, medical device manufacturers, and healthcare providers. Examples include Allergan, Pfizer, and Johnson & Johnson, as well as medical device companies such as Boston Scientific and Medtronic. Additionally, healthcare providers such as hospitals, clinics, and private practices offer treatments for vulvodynia. Show Less Read more